Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | HMGCR | P04035 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9124544 | 0.87 | — | — | |
| SCHEMBL12410629 | 0.84 | ALDH1A1 (0.30) | ALDH1A1TDP1GAA | |
| SCHEMBL243901 | 0.79 | TSHR (0.43) | ALDH1A1TDP1TRPA1HMGCRCHRM1 | |
| SCHEMBL2178900 | 0.79 | HMGCR (0.52) | ALDH1A1TDP1HMGCRCHRM1TBXA2R | |
| SCHEMBL10086138 | 0.78 | GAA (0.34) | ALDH1A1TDP1GAA | |
| Acetic Acid SCHEMBL1695867 | 0.77 | TSHR (0.42) | ALDH1A1TDP1TRPA1HMGCRCHRM1 | |
| SCHEMBL9842065 | 0.77 | LMNA (0.37) | ALDH1A1TDP1TRPA1HMGCRCHRM1 | |
| SCHEMBL9768492 | 0.77 | TSHR (0.42) | ALDH1A1TDP1TRPA1HMGCRCHRM1 | |
| SCHEMBL13880069 | 0.77 | ALDH1A1 (0.33) | ALDH1A1TDP1TRPA1HMGCRCHRM1 | |
| SCHEMBL13544793 | 0.77 | LMNA (0.38) | ALDH1A1TDP1HMGCRCHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3904367-A1 | TETRAPEPTIDE COMPOUND, PREPARATION METHOD AND USE THEREOF | Lanzhou University (CN) | 2021-11-03 | — | — | EP | disclosed |
| US-20170216248-A1 | Enhanced Erythropoiesis and Iron Metabolism | FIBROGEN, INC. | 2017-08-03 | — | — | US | disclosed |
| CN-103261402-B | Local flavor is regulated by using the biological treatment of the bacterial isolates forming cream-style | Nestle Products Technical Assistance Co.,Ltd. (CH) | 2015-10-07 | — | — | CN | disclosed |
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| CN-102037051-B | Water-dilutable amines and their use | SIKA TECHNOLOGY AG | 2014-12-24 | — | — | CN | disclosed |
| CN-102066452-B | Polyamine having reduced blushing effect, and use thereof as curing agent for epoxy resins | SIKA TECHNOLOGY AG | 2014-05-14 | — | — | CN | disclosed |
| US-20130245037-A1 | Stabilization of Hypoxia Inducible Factor (HIF) Alpha | FIBROGEN, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20120282353-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
| WO-2011033296-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2010112942-A1 | NOVEL DICARBOXYLIC ACID LINKED AMINO ACID AND PEPTIDE PRODRUGS OF OPIOIDS AND USES THEREOF | SHIRE LLC (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20090011051-A1 | Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds | FRED HUTCHINSON CANCER RESEARCH CENTER | 2009-01-08 | — | — | US | disclosed |
| US-5486451-A | FORMING A DISPERSION OF SILVER HALIDE GRAINS IN THE PRESENCE OF A HYDROPHILIC COLLOID AND REMOVING BY-PRODUCTS BY LOWERING THE PH TO BRING ABOUT COAGULATION | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1996-01-23 | — | — | US | disclosed |
| EP-0645672-A1 | Method for preparing silver halide photographic emulsions | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-03-29 | — | — | EP | disclosed |
| US-4082810-A | STEREOSELECTIVE HYDROGENATING AGENTS | ALDRICH-BORANES, INC. (US) | 1978-04-04 | — | — | US | disclosed |
| US-3960762-A | Production of absorbents | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080425-A1 | METHODS FOR TREATING ANEMIA IN SUBJECTS HAVING KIDNEY FAILURE USING INHIBITORS OF HYPOXIA-INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | ALDH1A1 503/4885TDP1 4838/4885TRPA1 4829/4885 |
| US-20130245037-A1 | Stabilization of Hypoxia Inducible Factor (HIF) Alpha | HIF1A, HIF1AN, EGLN2 | ALDH1A1 282/4885TDP1 4354/4885TRPA1 4390/4885 |
| US-20170216248-A1 | Enhanced Erythropoiesis and Iron Metabolism | EPOR, TFRC, HAMP | ALDH1A1 875/4885TDP1 4815/4885TRPA1 4885/4885 |
| US-20090011051-A1 | Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds | HIF1A, HIF1AN, EGLN3 | ALDH1A1 532/4885TDP1 4659/4885TRPA1 4037/4885 |
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | OPRM1, UGT1A6, UGT1A4 | ALDH1A1 327/4885TDP1 3075/4885TRPA1 568/4885 |
| US-20120282353-A1 | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR HIF MODULATING COMPOUNDS | HIF1A, HIF1AN, EGLN3 | ALDH1A1 532/4885TDP1 4659/4885TRPA1 4037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.